J.P. Morgan report examines tailwind opportunities in life science sector
In this recently issued report, the Co-Head of Healthcare and Life Sciences for J.P. Morgan Commercial Banking notes that the COVID-19 pandemic has drawn attention to the life science sector, thereby creating an enormous tailwind of opportunity. And this isn’t just contained to companies focusing on COVID-19; it’s across the board. The public is increasingly recognizing the novel innovation generated by life sciences star-tups, and investors have a renewed desire to deploy capital in the space.
The funding environment is also evolving, and it’s not clear where it will land. Until COVID-19 shocked the economy, valuations were on the rise, partnerships were booming, and startups were increasingly accessing liquidity through venture capital and the public markets.
There’s also an interview with Peter Meath in this article from MedCity News.
